Overview

Cell Therapy for Immunomodulation in Kidney Transplantation

Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This study investigates treatment with recipient regulatory T cells and donor bone marrow together with tocilizumab for immunomodulation in living donor kidney transplant recipients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Thomas Wekerle
Collaborator:
University Hospital Regensburg
Treatments:
Immunosuppressive Agents